The Harry and Elsa Jiler American Cancer Society Clinical Research Professorship

Publication
Article
OncologyONCOLOGY Vol 11 No 9
Volume 11
Issue 9

The American Cancer Society announces the establishment of the Harryand Elsa Jiler American Cancer Society Clinical Research Professorship

The American Cancer Society announces the establishment of the Harryand Elsa Jiler American Cancer Society Clinical Research Professorshipand invites interested candidates to submit proposals.

This prestigious grant is intended for an outstanding clinician-scientistin mid-career who has made significant contributions in cancer researchand is considered an exceptional leader in his/her field. Applicants maybe active in any area of clinical or epidemiologic cancer research, includingcancer control, clinical trials directed toward new therapeutic approaches,psychosocial and behavioral, health services, and health policy research.Translational laboratory research that has clinical application is alsoappropriate.

Candidates must be US citizens or permanent residents with at least10 years of experience beyond receipt of the MD or other doctoral degree.Individuals employed by for-profit organizations, federal agencies, oragencies supported entirely by the federal government are not eligible.At the time of the application, the candidate must have a full-time academicor comparable appointment. Generally, candidates must have obtained therank of associate or full professor or the equivalent; however, they mustnot have held the rank of full professor or equivalent for more than 15years.

The Harry and Elsa Jiler American Cancer Society Clinical Research Professorwill be chosen by a peer review process emphasizing past contributionsand future potential, but most importantly, innovation in the field andthe ability to attract young investigators into cancer research. The grantprovides up to $60,000 annually that can be apportioned to salary and/orresearch project support at the discretion of the awardee. The Professorshipwill be awarded for a period of 5 years and may be renewed once, contingentupon continued research productivity and leadership. The Harry and ElsaJiler American Cancer Society Clinical Research Professor will also berequired to be a spokesperson for the American Cancer Society.

The deadline for receipt of applications is October 1, 1997. Applicationsare furnished by the American Cancer Society after discussion with theScientific Program Director (Ralph Vogler, MD; 404-329-7542 or rvogler@cancer.org)or the Vice President for Extramural Grants (John Stevens, MD; 404-329-7550or jstevens@cancer.org) at the American Cancer Society, Inc., 1599 CliftonRoad, NE, Atlanta, GA 30329-4251, fax, 404-321-4669.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Related Content